HomeOverlooked Stock: BHVN

Overlooked Stock: BHVN

Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.

Market On Close

23 Sep 2024

SHARE

ON AIR
12:30 am
Gamma On
replay
12:00 am
Gamma On
REPLAY
ON AIR
12:30 am
Gamma On
REPLAY
1:00 am
Gamma On
REPLAY
1:30 am
Gamma On
REPLAY
2:30 am
Gamma On
REPLAY
3:00 am
Gamma On
REPLAY
3:30 am
Gamma On
REPLAY
4:00 am
Gamma On
REPLAY
5:00 am
Gamma On
REPLAY
6:00 am
Gamma On
REPLAY
education
7:00 am
Inside the Mind of a Trader
REPLAY
education
7:30 am
Inside the Mind of a Trader
REPLAY
education
8:00 am
Inside the Mind of a Trader
REPLAY
8:30 am
Market Overtime
REPLAY
9:00 am
Gamma On
REPLAY
9:30 am
Gamma On
REPLAY
10:00 am
Gamma On
REPLAY
10:30 am
Gamma On
REPLAY
11:30 am
Gamma On
REPLAY
12:00 pm
Gamma On
REPLAY
12:30 pm
Gamma On
REPLAY
1:00 pm
Gamma On
REPLAY
2:00 pm
Gamma On
REPLAY
3:00 pm
Gamma On
REPLAY
education
4:00 pm
Your First Trade
REPLAY
education
4:30 pm
Your First Trade
REPLAY
education
5:00 pm
Your First Trade
REPLAY
education
5:30 pm
Your First Trade
REPLAY
education
6:00 pm
Your First Trade
REPLAY
6:30 pm
Market Overtime
REPLAY
7:00 pm
Gamma On
REPLAY
8:00 pm
Gamma On
REPLAY
9:00 pm
Trading 360
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Get the Market Minute

Daily insights for every investor